| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.2 | 0.6 |
| Gross profit | 0.1 | 0.2 |
| Profit before tax | -22.3 | -35.7 |
| Net income | -22.3 | -35.7 |
| EPS (diluted, $ a share) | $-0.10 | $-0.17 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -61.6% |
|---|---|
| Gross margin | 34.9% |
10-Q filed with the SEC, NASDAQ: QSI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Quantum-Si Inc: key numbers
- Share price
- $1.06Close, Nov 16
- Sector
- Industrial Applications and Services
- Industry
- Measuring & Controlling Devices, NECSIC 3829
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Quantum-Si Inc
All →Quantum-Si Financial Results
Quantum-Si reported third quarter 2026 revenue of $212,000, reflecting a transition period as the company prepares for the commercial launch of its Proteus platform in Q2 2027. The company updated its full-year 2026 guidance to reflect lower operating expenses and cash usage, while reaffirming its cash runway into the fourth quarter of 2028.
“We made significant progress during the third quarter as we continued to advance Proteus toward commercial launch. Based on recent performance data, we believe we have substantially addressed the instrument variability issues identified earlier in development, and design activities for our additional instrument cycle are now complete.”
Jeff Hawkins, President and Chief Executive Officer
“At World HUPO, we demonstrated that Proteus significantly outperformed Platinum Pro across key measures of sequencing performance. While we are encouraged by these results, we believe the Proteus platform we ultimately launch will meaningfully exceed the performance demonstrated in this interim study.”
Jeff Hawkins, President and Chief Executive Officer
Quantum-Si Nasdaq/NYSE Compliance Notice
Quantum-Si Incorporated has regained compliance with Nasdaq's minimum bid price requirement as its Class A common stock maintained a closing bid price of at least $1.00 per share for 10 consecutive business days. The company had previously received a deficiency notice on July 23, 2026, and Nasdaq has now officially closed the matter.
- Counterparty
- Nasdaq
Quantum-Si Business Update
Quantum-Si announced it has successfully demonstrated the detection of 19 amino acids within its Proteus development program, a key technical milestone for its single-molecule protein sequencing platform. The company remains on track to demonstrate detection of all 20 amino acids by the end of 2026 and expects a commercial launch of the Proteus platform in the second quarter of 2027.
Quantum-Si Investor Presentation
Quantum-Si Incorporated filed a formal investor presentation deck (Exhibit 99.1) titled 'Proteus: The Future of Single-molecule Protein Sequencing' for use at the World HUPO 2026 conference in Singapore. The presentation provides updates on the development and commercialization of the Proteus platform, including its amino acid detection capabilities and system integration progress.